Maralixibat

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cholestatic Liver Disease

Conditions

Cholestatic Liver Disease

Trial Timeline

Jan 16, 2020 → Sep 4, 2024

NCT ID

NCT04168385

About Maralixibat

Maralixibat is a phase 2 stage product being developed by Mirum Pharmaceuticals for Cholestatic Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04168385. Target conditions include Cholestatic Liver Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04530994	Pre-clinical	Completed	—	—	Alagille Syndrome
NCT07389031	Phase 2	Recruiting	Apr 1, 2026	Mar 31, 2028	Intrahepatic Cholestasis of Pregnancy
NCT06553768	Phase 3	Recruiting	Oct 14, 2024	Feb 1, 2027	Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
NCT04729751	Phase 2	Completed	Sep 9, 2021	Dec 17, 2024	Progressive Familial Intrahepatic Cholestasis
NCT04524390	Phase 2	Completed	Jul 8, 2021	Feb 7, 2024	Biliary Atresia
NCT04168385	Phase 2	Completed	Jan 16, 2020	Sep 4, 2024	Cholestatic Liver Disease
NCT04185363	Phase 3	Completed	Jan 8, 2020	Apr 23, 2025	Progressive Familial Intrahepatic Cholestasis (PFIC)
NCT03905330	Phase 3	Completed	Jul 9, 2019	Sep 1, 2022	Progressive Familial Intrahepatic Cholestasis (PFIC)

Competing Products

3 competing products in Cholestatic Liver Disease

See all competitors

Product	Company	Stage	Hype Score
A4250 + CRC (A3384) + Questran + Placebo	Ipsen	Phase 1	30
3 mg [14C]-A4250 capsule	Ipsen	Phase 1	30
Maralixibat	Mirum Pharmaceuticals	Phase 3	74

Other Products from Mirum Pharmaceuticals

Livmarli Oral ProductApproved